Target RWE
Meg Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. She is currently serving as Board Chair and is the Co-Founder of Target RWE.
Meg has worked with multiple start-up companies while at Medgility, a consulting firm focused on strategy and business development of emerging companies. These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.
Prior to her work at Medgility, Meg was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and global development programs at all stages – from phase 1 to post patent expiry.
Meg received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University.
This person is not in the org chart
This person is not in any offices
Target RWE
As the industry’s best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives. Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Their rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model.